Yong Cheng1,2,3, Li Yuan1,2,3, Ming-Wei Zhao1,2,3, Tong Qian1,2,3. 1. Department of Ophthalmology, People's Hospital, Peking University, Beijing 100044, China. 2. Eye Diseases and Optometry Institute, College of Optometry, Peking University Health Science Center, Beijing 100044, China. 3. Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China.
Abstract
AIM: To evaluate the two-year outcomes of patients treated for diabetic macular edema (DME) with intravitreal Conbercept (IVC). METHODS: The clinical data of 30 DME patients (36 eyes) were retrospectively reviewed. The patients were treated with IVC for 3mo. Additional IVC was given at subsequent monthly visits, if needed (3+PRN). The patients were followed up for 24mo. RESULTS: The best-corrected visual acuity (BCVA) at 24mo significantly increased (66.7±15.3 letters) in comparison with the baseline (54.4±15.4 letters, P<0.0001). The mean improvement in BCVA was 11.0±2.9 letters. At 24mo, 44.1% of the eyes surveyed gained ≥15 letters, 52.9% of the eyes gained ≥10 letters, and 70.6% of the eyes gained ≥5 letters. No vision loss was noted in 96.8% of the eyes, and 5.9% of the eyes lost ≥5 letters, but ≤10 letters. The central retinal thickness (CRT) at 24mo was significantly reduced (277.1±122.9 µm) in comparison with the baseline (510.9±186.1 µm, P<0.0001). At 24mo, 43.3% of the patients had a CRT ≤250 µm. The mean number of injections over 24mo was 10.6±2.0. No severe eye or systemic adverse events related to either the drug or injection were noted. CONCLUSION: IVC is safe and effective for the treatment of DME. International Journal of Ophthalmology Press.
AIM: To evaluate the two-year outcomes of patients treated for diabetic macular edema (DME) with intravitreal Conbercept (IVC). METHODS: The clinical data of 30 DMEpatients (36 eyes) were retrospectively reviewed. The patients were treated with IVC for 3mo. Additional IVC was given at subsequent monthly visits, if needed (3+PRN). The patients were followed up for 24mo. RESULTS: The best-corrected visual acuity (BCVA) at 24mo significantly increased (66.7±15.3 letters) in comparison with the baseline (54.4±15.4 letters, P<0.0001). The mean improvement in BCVA was 11.0±2.9 letters. At 24mo, 44.1% of the eyes surveyed gained ≥15 letters, 52.9% of the eyes gained ≥10 letters, and 70.6% of the eyes gained ≥5 letters. No vision loss was noted in 96.8% of the eyes, and 5.9% of the eyes lost ≥5 letters, but ≤10 letters. The central retinal thickness (CRT) at 24mo was significantly reduced (277.1±122.9 µm) in comparison with the baseline (510.9±186.1 µm, P<0.0001). At 24mo, 43.3% of the patients had a CRT ≤250 µm. The mean number of injections over 24mo was 10.6±2.0. No severe eye or systemic adverse events related to either the drug or injection were noted. CONCLUSION: IVC is safe and effective for the treatment of DME. International Journal of Ophthalmology Press.
Authors: Pascale Massin; Francesco Bandello; Justus G Garweg; Lutz L Hansen; Simon P Harding; Michael Larsen; Paul Mitchell; Dianne Sharp; U E K Wolf-Schnurrbusch; Margarita Gekkieva; Andreas Weichselberger; Sebastian Wolf Journal: Diabetes Care Date: 2010-11 Impact factor: 19.112
Authors: Roy W Beck; Allison R Edwards; Lloyd P Aiello; Neil M Bressler; Frederick Ferris; Adam R Glassman; Elizabeth Hartnett; Michael S Ip; Judy E Kim; Craig Kollman Journal: Arch Ophthalmol Date: 2009-03
Authors: Susan B Bressler; Adam R Glassman; Talat Almukhtar; Neil M Bressler; Frederick L Ferris; Joseph M Googe; Shailesh K Gupta; Lee M Jampol; Michele Melia; John A Wells Journal: Am J Ophthalmol Date: 2016-01-21 Impact factor: 5.258
Authors: Michael Whitehead; Sanjeewa Wickremasinghe; Andrew Osborne; Peter Van Wijngaarden; Keith R Martin Journal: Expert Opin Biol Ther Date: 2018-11-14 Impact factor: 4.388